Abstract
This study determined whether alkaline phosphatase can be used to distinguish giant cell arthritis complications in patients with polymyalgia rheumatica. This retrospective study included patients diagnosed with polymyalgia rheumatica between January 2014 and October 2023 at our hospital. The predictive accuracy of biomarkers for diagnosing giant cell arthritis was evaluated. Logistic regression was performed to identify factors predicting giant cell arthritis complications. In total, 128 participants were included in this study and divided into two groups: isolated polymyalgia rheumatica (n = 111) and polymyalgia rheumatica with giant cell arthritis (n = 17). The median alkaline phosphatase level of polymyalgia rheumatica with giant cell arthritis group was significantly higher than that of the isolated polymyalgia rheumatica group (242.0 [interquartile range, 221.0-595.0] vs. 187.0 [interquartile range 97.5-254.5] U/L, P < 0.001). Setting a cut-off value of 214 U/L for alkaline phosphatase yielded a sensitivity and specificity of 0.88 and 0.55, respectively, for diagnosing giant cell arteritis. Multivariate analysis revealed that alkaline phosphatase was a significant independent variable in the complications of giant cell arteritis (odds ratio, 25.2; P = 0.032). Alkaline phosphatase can help distinguish giant cell arthritis complications in patients with polymyalgia rheumatica.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
